Results 181 to 190 of about 257,826 (338)

Prolongation of skin homografts in rabbits, using cyclophosphamide

, 1964
Jerry Jones, Gerald L. Brody, Robert M. O’Neal, Richard F. Haines   +3 more
openalex   +1 more source

Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan [PDF]

, 1975
Jeremy Millar, B N Hudspith, N. M. Blackett   +2 more
openalex   +1 more source

Myeloablative autologous stem-cell transplantation for severe scleroderma [PDF]

, 2018
Brasington, R., et al,
core   +1 more source

Cyclophosphamide: An Overview

Clinical Dermatology Review
Cyclophosphamide (CPE) is an alkylating agent that has shown to have a wide range of applications in dermatology. Although not a first-line drug for any of the dermatological disorders, it has been found to be useful as a second-line drug in unresponsive cases. A major drawback of CPE is its toxicity profile.
openaire   +2 more sources

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy

The Journal of Pathology, EarlyView.
Abstract In recent years, targeted therapies have become the standard of care for refractory/relapsed mantle cell lymphoma (MCL). Although the mutational profile of MCL has been extensively studied, there is a lack of understanding of resistance mechanisms and genetic factors that impact the response to novel treatments.
Tamás László, László Imre Pinczés, Bence Bátai, Luca Varga, Botond Timár, Anita Gulyás, Ilona Tárkányi, Márk Plander, Zsolt Nagy, Péter Rajnics, Miklós Egyed, Zsuzsa Molnár, János Rottek, András Masszi, Péter Tamáska, Róbert Szász, Árpád Illés, Donát Alpár, Ferenc Magyari, Csaba Bödör   +19 more
wiley   +1 more source

Book Review: Cyclophosphamide (Endoxana)

, 1965
E. Wiltshaw
openalex   +1 more source

Immunoresponsiveness of patients with rheumatoid arthritis receiving cyclophosphamide or gold salts. [PDF]

, 1973
Jolene Strong, Barbara Bartholomew, Charley J. Smyth   +2 more
openalex   +1 more source

Analysis of Late Complications Associated With Hematopoietic Stem Cell Transplantation in Patients With Dyskeratosis Congenita

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Dyskeratosis congenita (DKC) is a genetic disorder frequently complicated by bone marrow failure (BMF). Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option for BMF in DKC. However, late complications of DKC, especially pulmonary fibrosis (PF), pose significant challenges.
Takashi Koike, Shohei Yamamoto, Mayuko Shibata, Kohei Otsuka, Yumiko Sugishita, Ryota Kaneko, Naoko Kawabata, Sachio Fujita, Kosuke Akiyama, Daisuke Toyama, Miharu Yabe, Atsushi Uchiyama, Hiromasa Yabe   +12 more
wiley   +1 more source

Comparison of outcomes in feline intermediate- to large-cell lymphoma treated with CMOP (cyclophosphamide, mitoxantrone, vincristine and prednisolone) instead of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone). [PDF]

J Feline Med Surg
Lai NA, Nguyen SM, Todd JE, Langova V, Bavcar S, Blaxill JE, Yu S, White JD.   +7 more
europepmc   +1 more source

Evaluation of Pediatric and Young Adult Cancer Survivors at Risk of Long‐Term Kidney Complications

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Nephrotoxic chemotherapy, nephrectomy, abdominal radiotherapy exposure, and the presence of kidney or pelvic tumors are risk factors associated with long‐term kidney complications. This study aimed to determine the prevalence of long‐term kidney complications in patients who survived pediatric and young adult cancer and were exposed
Ahmed Zeid, Sara Delap, Claudia Mosquera Vasquez, Randal S. Olshefski, Joseph R. Stanek, Lory Guthrie, Diana Zepeda‐Orozco   +6 more
wiley   +1 more source